IDH2 and glioblastoma: So, when analyzing results from studies published before 2021 or clinical trials initiated before this date, one should be aware that the group of patients previously classified as having GBM may also include those with IDH1/IDH2 mutations, which would not be diagnosed as GBM according to the current WHO classification [35].